Cryoport, Inc.

Listed Company

CYRXCIK 0001124524NasdaqAcceleratedPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

$176.18M

Net Income

$78.30M

Total Assets

$764.99M

Equity

$502.64M

Shares Out

50.40M

Op. Cash Flow

$-8.58M

CYRX$16.51+122.14% · past yearDBEQ Basic

Daily closing prices

Business

Cryoport is a leading global provider of integrated, temperature-controlled supply chain solutions for life sciences, with particular focus on cell and gene therapies. The company offers BioLogistics (specialized transport), BioStorage (long-term biostorage), BioServices (kit production, labeling, fulfillment), Cryopreservation services (IntegriCell platform), and manufactures cryogenic systems (freezers, dewars, transport vessels) through MVE Biological Solutions. Cryoport operates a Global Supply Chain Center Network across the Americas, EMEA, and APAC regions, serving biopharmaceutical companies, research institutions, and government agencies.

Summary from 10-K filed 2026-03-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	176	157	169	237	223
Total cost of revenue	93	87	93	133	126
Gross margin	83	70	75	104	97
Selling, general and administrative	103	110	108	120	98
Engineering and development	17	18	18	16	17
Impairment loss	—	64	50	—	—
Total operating costs and expenses	120	191	176	136	114
Loss from operations	−37	−122	−101	−32	−18
Investment income	10	10	11	8	3
Interest expense, net	−2	−4	−6	−6	—
Gain on extinguishment of debt, net	—	19	6	—	−252
Other income (expense), net	−3	−7	6	−6	−3
Total other income, net	5	17	16	−3	−256
Loss from continuing operations before provision for income taxes	−32	−104	−84	−35	−274
Provision for income taxes	−2	−359,000	−345,000	−2	−2
Loss from continuing operations	−34	−105	−85	—	—
Income (loss) from discontinued operations, net	112	−10	−15	—	—
Net income (loss)	78	−115	−100	−37	−276
Paid-in-kind dividend on Series C convertible preferred stock	−8	−8	−8	−8	−8
Net income (loss) attributable to common stockholders	70	−123	−108	−45	−284
Net loss per share from continuing operations - basic (in dollars per share)	−0.84	−2.29	−1.9	—	—
Net income (loss) per share from discontinued operations - basic (in dollars per share)	2.24	−0.2	−0.31	—	—
Net income (loss) per share - basic (in dollars per share)	1.4	−2.49	−2.21	−0.93	−6.18
Weighted average common shares issued and outstanding - basic (in shares)	50	49	49	49	46
Net loss per share from continuing operations - diluted (in dollars per share)	−0.84	−2.29	−1.9	—	—
Net income (loss) per share from discontinued operations - diluted (in dollars per share)	2.24	−0.2	−0.31	—	—
Net income (loss) per share - diluted (in dollars per share)	1.4	−2.49	−2.21	−0.93	−6.18
Weighted average common shares issued and outstanding - diluted (in shares)	50	49	49	49	46

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	250	34	35	29	139
Short-term investments	161	216	410	487	490
Accounts receivable, net	33	25	42	44	39
Inventories	23	21	26	28	17
Prepaid expenses and other current assets	8	8	10	9	9
Current assets held for sale	—	36	—	—	—
Total current assets	476	342	535	604	694
Property and equipment, net	85	80	85	64	49
Operating lease right-of-use assets	40	40	33	27	21
Intangible assets, net	138	148	194	191	201
Goodwill	22	21	76	151	147
Deposits	2	2	2	1	950,000
Deferred tax assets	1	842,000	656,000	947,000	—
Long-term assets held for sale	—	71	—	—	—
Total assets	765	703	958	1,039	1,113
Accounts payable and other accrued expenses	15	16	27	28	29
Accrued compensation and related expenses	13	11	11	8	10
Deferred revenue	943,000	1	1	439,000	547,000
Current portion of operating lease liabilities	4	3	5	4	4
Current portion of finance lease liabilities	422,000	315,000	286,000	128,000	61,000
Current portion of convertible senior notes, net of discount of $1.1 million and $0.1 million, respectively	185	14	—	—	—
Current portion of notes payable	163,000	143,000	149,000	60,000	—
Current portion of contingent consideration	—	3	92,000	—	—
Current liabilities held for sale	—	15	—	—	—
Total current liabilities	219	65	46	41	43
Convertible senior notes, net of current portion and discount of $0 and $2.3 million, respectively	—	184	379	407	404
Notes payable, net of current portion	1	1	1	355,000	1
Operating lease liabilities, net of current portion	39	39	29	25	18
Finance lease liabilities, net of current portion	741,000	800,000	954,000	216,000	51,000
Deferred tax liabilities	1	804,000	3	5	4
Other long-term liabilities	444,000	295,000	601,000	451,000	298,000
Contingent consideration, net of current portion	629,000	4	9	5	—
Long-term liabilities held for sale	—	8	—	—	—
Total liabilities	262	302	469	483	471
Commitments and contingencies	—	—	—	—	—
Common stock, $0.001 par value; 100,000,000 shares authorized; 49,850,793 and 49,908,254 issued and outstanding at December 31, 2025 and December 31, 2024, respectively	50,000	50,000	49,000	48,000	50,000
Additional paid-in capital	1,153	1,146	1,131	1,115	—
Accumulated deficit	−689	−757	−642	−543	−468
Accumulated other comprehensive loss	−3	−21	−26	−35	—
Total stockholders' equity	503	402	489	556	642
Total liabilities and stockholders' equity	765	703	958	1,039	1,113

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	78	−115	−100	−37	—
Depreciation and amortization	28	31	27	23	20
Amortization of debt discount	1	2	3	3	1
Non-cash operating lease expense	7	6	5	4	3
Unrealized (gain) loss on investments in equity securities	−2	899,000	−1	11	1
Realized loss on investments in equity securities	—	48,000	—	—	—
Realized loss on available-for-sale investments	2	4	100,000	100,000	80,000
Gain on divested business	−117	—	—	—	—
Stock-based compensation expense	11	20	23	20	15
Loss on disposal of property and equipment	1	384,000	954,000	800,000	542,000
Gain on insurance settlement	—	—	−3	−5	0
Change in credit losses	304,000	−242,000	822,000	234,000	—
Excess and obsolete inventory	393,000	234,000	—	651,000	0
Insurance proceeds for operations	—	—	1	10	0
Change in contingent consideration	−5	−2	−890,000	216,000	0
Accounts receivable	−7	−4	4	−4	−7
Inventories	−2	3	2	−14	−6
Prepaid expenses and other current assets	1	−2	−103,000	−2	3
Deposits	−189,000	−1	−663,000	−60,000	211,000
Operating lease liabilities	−5	−5	−5	−3	−3
Accounts payable and other accrued expenses	−3	−76,000	−3	−6	−398,000
Accrued compensation and related expenses	2	2	3	−2	3
Deferred revenue	−216,000	−179,000	842,000	−530,000	102,000
Net deferred tax liability	661,000	−377,000	−2	−411,000	231,000
Net cash used in operating activities	−9	−16	−757,000	−2	8
Purchases of property and equipment	−16	−17	−39	−22	−24
Insurance proceeds for loss of fixed assets	—	—	976,000	3	—
Software development costs	−2	−3	−5	−1	−870,000
Purchases of short-term investments	—	−51	−43	−164	−483
Proceeds from divested business	210	—	—	—	—
Cash paid for acquisitions	—	−313,000	−7	−7	−6
Sales/maturities of short-term investments	60	249	130	132	44
Patent and trademark costs	−1	−1	−871,000	−614,000	−255,000
Net cash provided by investing activities	250	177	36	−60	−469
Proceeds from exercise of stock options	4	3	1	—	—
Repurchase of common stock	−10	—	—	−38	0
Repayment of notes payable	−161,000	−141,000	−71,000	−3	−3
Repayment of finance lease liabilities	−530,000	−408,000	−202,000	−82,000	−60,000
Net cash used in financing activities	−21	−162	−24	−39	564
Effect of exchange rates on cash and cash equivalents	−15	−18,000	−2	−2	−986,000
Net change in cash and cash equivalents	205	−1	10	−103	102
Cash paid for interest	2	3	3	4	3
Cash paid for income taxes	2	1	1	2	1
Operating lease right-of-use assets and operating lease liabilities	7	21	11	12	10
Net unrealized gain on available-for-sale debt securities	2	3	7	23	4
Reclassification of realized gain (loss) on available-for-sale debt securities to earnings	3	−7	−3	46,000	27,000
Paid-in-kind preferred stock dividend, including beneficial conversion feature	8	8	8	8	8
Fixed assets included in accounts payable and accrued liabilities	218,000	103,000	442,000	1	1
Intangible assets included in property and equipment	—	252,000	9	—	—
Contingent consideration reclassed to accounts payable and accrued liabilities	881,000	—	—	—	—
Purchase of equipment through finance lease obligation	388,000	936,000	1	—	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Cryoport, Inc.'s CIK number?

Cryoport, Inc.'s SEC CIK number is 0001124524 (1124524). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Cryoport, Inc.'s SEC filings?

All of Cryoport, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Cryoport, Inc. last report earnings?

Cryoport, Inc. (CYRX) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-054942). This is Cryoport, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Cryoport, Inc.'s most recent earnings 8-K?

Cryoport, Inc.'s latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001104659-26-054942. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Cryoport, Inc.'s latest earnings 8-K →
Look up any company's CIK number →